- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Restructuring in U.S. trims Kodak sales
Eastman Kodak reporteda 3% decline in revenue last week for its Health Group, whichincludes x-ray film, electronic imaging products and SterlingWinthrop contrast agents, as well as the nonimaging Sterling pharmaceuticalbusiness. X-ray products gained in
Eastman Kodak reporteda 3% decline in revenue last week for its Health Group, whichincludes x-ray film, electronic imaging products and SterlingWinthrop contrast agents, as well as the nonimaging Sterling pharmaceuticalbusiness. X-ray products gained in volume for the period, Kodaksaid. Overall revenues at the film giant were up 1% for the firstquarter (end-March).
Kodak attributed its Health Group's weak performance to theongoing restructuring in U.S. health-care markets. Total HealthGroup revenues dropped to $1.2 billion in the first quarter of1994, from $1.25 in the same period of last year. Revenue in theinternational segment of Kodak's Health Group actually rose 5%,while U.S. revenue was down 9%.
Health Group earnings from operations rose 17% for the quarterfrom $118 million in 1993 to $138 million. This rise in operatingearnings was the lowest of Kodak's three industry segments ofImaging (general photographic), Information and Health. Kodak'stotal worldwide revenue in the first quarter was $3.6 billion.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
